Management of High-Risk HPV-Positive Oropharyngeal Cancer
2016 AAO-HNSF Annual Meeting &OTO EXPOSM
Keyword(s)
oropharyngeal squamous cell carcinoma (OPSCC), human papillomavirus (HPV), management of high-risk HPV oropharyngeal squamous cell carcinoma
It is estimated that approximately 60-70% of new oropharyngeal squamous cell carcinoma (OPSCC) cases are attributable to human papillomavirus (HPV). While the majority of HPV-positive OPSCC patients experience excellent oncologic outcomes, there is a subset of patients with aggressive disease who develop persistent or recurrent cancer after primary treatment. In the current era of treatment de-intensification for HPV-positive OPSCC, identifying high-risk patients who would benefit from more aggressive therapy is essential. In this seminar, we review clinical and genomic data to more effectively define high-risk HPV-positive OPSCC. The purpose of this seminar is 1) to discuss patterns of recurrence, metastasis, and survival in HPV-positive OPSCC, 2) to identify clinical and molecular characteristics of high-risk HPV-positive OPSCC, 3) identify indications and contraindications to OPSCC treatment de-intensification, 4) discuss the role of transoral surgery in the management of high risk HPV-positive OPSCC.
Description
It is estimated that approximately 60-70% of new oropharyngeal squamous cell carcinoma (OPSCC) cases are attributable to human papillomavirus (HPV). While the majority of HPV-positive OPSCC patients experience excellent oncologic outcomes, there is a subset of patients with aggressive disease who develop persistent or recurrent cancer after primary treatment. In the current era of treatment de-intensification for HPV-positive OPSCC, identifying high-risk patients who would benefit from more aggressive therapy is essential. In this seminar, we review clinical and genomic data to more effectively define high-risk HPV-positive OPSCC. The purpose of this seminar is 1) to discuss patterns of recurrence, metastasis, and survival in HPV-positive OPSCC, 2) to identify clinical and molecular characteristics of high-risk HPV-positive OPSCC, 3) identify indications and contraindications to OPSCC treatment de-intensification, 4) discuss the role of transoral surgery in the management of high risk HPV-positive OPSCC. Learning Objectives:1: Discuss epidemiology and oncologic outcomes in HPV-positive oropharyngeal squamous cell carcinoma, and to identify a high-risk subset of patients who fail primary treatment or develop recurrent cancer. 2: Discuss the clinical and molecular characteristics of high-risk HPV-positive oropharyngeal squamous cell carcinoma. 3: Discuss the appropriate management of high-risk HPV oropharyngeal squamous cell carcinoma, and to identify appropriate indications for treatment deintensification in HPV-positive oropharyngeal squamous cell carcinoma.Faculty:Jose P. Zevallos, MD, MPH (No relationships to disclose), David Neil Hayes, MD, MPH (GeneCentric: Consultant/Advisory Board, Consulting Fees (e.g., advisory boards), Ownership Interest, Stockholder/Ownership Interest (excluding diversified mutual funds)), Bhishamjit Chera, MD (No relationships to disclose), Carole Fakhry, MD, MPH (No relationships to disclose), Umamaheswar Duvvuri, MD, PhD (No relationships to disclose).
